Therapies Development Targeting Type IV Pili of P. Aeruginosa

One of the key virulence factors of P. aeruginosa is its ability to form Type IV pili, which play a crucial role in the colonization and persistence of the bacterium in various host tissues. Through a comprehensive understanding of the molecular mechanisms underlying Type IV pili biogenesis and function, we aim to design innovative therapies that can disrupt bacterial pathogenicity and resistance.

Ace Therapeutics is at the forefront of developing therapies targeting superbugs. Our multidisciplinary team of experts is dedicated to advancing these novel therapeutic strategies such as targeting Type IV pili, ultimately contributing to the fight against antibiotic-resistant superbugs and improving the efficacy of existing treatment approaches.

Introduction to Type IV Pili of P. Aeruginosa

Type IV pili are long, thin, filamentous appendages found on the surface of many bacteria, including P. aeruginosa. These pili are composed of pilin subunits and are involved in diverse biological functions, including twitching motility, adherence to host cells, and biofilm formation. The dynamic nature of Type IV pili enables P. aeruginosa to establish and maintain infections, making them an attractive target for the development of novel therapeutic strategies.

Schematic of the type IVa pilus system in P. aeruginosa.Fig. 1 Schematic of the type IVa pilus system in P. aeruginosa. (Leighton T L, et al., 2015)

Our Development Services for Targeted Therapy

With our expertise in drug development and biotechnology, we offer comprehensive services aimed at developing therapies targeting Type IV pili of P. aeruginosa. Our research and development efforts encompass the following:

Targeting pilin assembly

Through a combination of computational modeling, structural biology, and high-throughput screening, we can identify small molecules or peptides that can selectively inhibit pilin assembly, thereby preventing the formation of functional pili.

Inhibiting pilus retraction

By targeting the machinery responsible for pilus retraction, we can impair the bacteria's ability to move and adhere to host tissues. We can identify key components involved in pilus retraction and develop inhibitors that disrupt this process.

Disrupting pilus-mediated adhesion

By developing molecules or peptides that specifically bind to pilin subunits or interfere with pilus-host cell interactions, we aim to prevent bacterial attachment and subsequent biofilm formation.

Approaches for Therapy Development

We employ a range of cutting-edge approaches and technologies to unravel the intricacies of Type IV pili and design effective therapies.

  • Inhibitors-based approach. These inhibitors can target specific proteins involved in pilus biogenesis.
  • Antibodies-based approach. Another approach involves developing antibodies that specifically recognize and bind to Type IV pili of P. aeruginosa.
  • Vaccines-based approach. This approach involves developing vaccines that induce an immune response against Type IV pili or specific pilus proteins.

Potential Applications

Our innovative approaches may offer several advantages, including:

  • Enhanced efficacy
  • Reduced resistance development
  • Combination therapy
  • Prevention of biofilm formation

Our team of experts is dedicated to advancing these novel therapeutic strategies. Please contact us to work with us for more development information.


  1. Leighton T L, et al. Biogenesis of P. seudomonas aeruginosa type IV pili and regulation of their function. Environmental microbiology, 2015, 17(11): 4148-4163.
  2. Persat A, et al. Type IV pili mechanochemically regulate virulence factors in Pseudomonas aeruginosa. Proceedings of the National Academy of Sciences, 2015, 112(24): 7563-7568.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Get in touch with our team immediately.